July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Subconjunctival bevacizumab injections in the management of impending recurrent pterygium
Author Affiliations & Notes
  • Ying Chen
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, United States
    Miller School of Medicine, University of Miami, Miami, Florida, United States
  • Harry Levine
    Miller School of Medicine, University of Miami, Miami, Florida, United States
  • Ann Quan
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, United States
    Miller School of Medicine, University of Miami, Miami, Florida, United States
  • Raquel Goldhardt
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, United States
    Ophthalmology, Miami Veterans Affair Hospital, Miami, Florida, United States
  • Anat Galor
    Ophthalmology, Bascom Palmer Eye Institute, Miami, Florida, United States
    Ophthalmology, Miami Veterans Affair Hospital, Miami, Florida, United States
  • Footnotes
    Commercial Relationships   Ying Chen, None; Harry Levine, Consejo Nacional de Ciencia y Tecnologia CVU810654 (R); Ann Quan, None; Raquel Goldhardt, None; Anat Galor, Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S (R), Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research R01EY026174 (R), NIH Center Core Grant P30EY014801 (R), Research to Prevent Blindness Unrestricted Grant (R)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6269. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ying Chen, Harry Levine, Ann Quan, Raquel Goldhardt, Anat Galor; Subconjunctival bevacizumab injections in the management of impending recurrent pterygium. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6269.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the effect of subconjunctival injections of bevacizumab on ocular discomfort and cosmetic appearance in eyes with an impending recurrent pterygium after surgical excision.

Methods : Retrospective chart review of four patients treated at the Miami Veteran’s Affairs Medical Center. Subconjunctival bevacizumab (0.1ml) was administered based on persistent bulbar hyperemia in the area of the autograft 1 month (n=1) or 3 months post-op (n=3). The number of injections administered was based on clinical response with one subject receiving one injection and the other three receiving three injections, one month apart. Ocular discomfort scores were assessed before and after treatment. Cosmetic outcomes were assessed via clinical photos taken before and after treatment.

Results : The median age was 55.5 years (range 33-72), three were male and one was female; two patients were Caucasian, and two self-identified as Hispanic. All patients initially underwent pterygium excision with conjunctival autograft; three with concomitant 0.02% Mitomycin C and three with amniotic membrane placement over the autograft for primary pterygium (n=2), recurrent pterygium (n=1), or pseudo-pterygium after trauma (n=1). Ocular discomfort scores improved in all individuals after bevacizumab injections with improved symptoms of irritation and foreign body sensation. Bulbar hyperemia resolved in 3 eyes (two primary and one recurrent pterygium) with no pterygium recurrence and excellent cosmetic outcomes noted after 3 months of follow up. The patient with a pseudo-pterygium experienced a recurrence despite 3 bevacizumab injections, and the lesion appeared similar to that noted pre-operatively on 3 months follow up after the last injection. One patient was on concomitant use of steroids at the time of bevacizumab treatment.

Conclusions : Subconjunctival injections of bevacizumab improved bulbar hyperemia in individuals with impending recurrence after pterygium removal. However, injections did not prevent recurrence in a case of pseudo-pterygium secondary to ocular trauma.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×